Puretech advances wholly-owned candidate lyt-300 (oral allopregnanolone) into clinical study for potential treatment of neurological and neuropsychological conditions

Boston--(business wire)--puretech initiated a clinical study of lyt-300 (oral allopregnanolone), its wholly-owned therapeutic candidate.

PRTC Ratings Summary

PRTC Quant Ranking